Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.

Journal of Thrombosis and Thrombolysis
Dominick J AngiolilloRichard C Becker

Abstract

Cangrelor is an intravenous antagonist of the P2Y(12) receptor characterized by rapid, potent, predictable, and reversible platelet inhibition. However, cangrelor was not superior to clopidogrel in reducing the incidence of ischemic events in the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. A prospectively designed platelet function substudy was performed in a selected cohort of patients to provide insight into the pharmacodynamic effects of cangrelor, particularly in regard to whether cangrelor therapy may interfere with the inhibitory effects of clopidogrel. This pre-defined substudy was conducted in a subset of patients from the CHAMPION-PCI trial (n = 230) comparing cangrelor with 600 mg of clopidogrel administered before percutaneous coronary intervention (PCI) and from the CHAMPION-PLATFORM trial (n = 4) comparing cangrelor at the time of PCI and 600 mg clopidogrel given after the PCI. Pharmacodynamic measures included P2Y12 reaction units (PRU) assessed by VerifyNow P2Y12 testing (primary endpoint marker), platelet aggregation by light transmittance aggregometry following 5 and 20 μmol/L adenosine diphosphate stimuli, and markers of platelet activation determin...Continue Reading

Associated Clinical Trials

References

Jun 23, 2001·The New England Journal of Medicine·E J TopolUNKNOWN TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial
Feb 28, 2002·The American Journal of Cardiology·Samer S KabbaniDavid J Schneider
Apr 10, 2007·Journal of the American College of Cardiology·Dominick J AngiolilloMarco A Costa
Jul 17, 2007·Thrombosis Research·Steven R SteinhublWendell S Akers
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Mar 7, 2009·Journal of the American College of Cardiology·Dirk SibbingNicolas von Beckerath
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Oct 10, 2009·Expert Review of Cardiovascular Therapy·José Luis FerreiroDominick J Angiolillo
Nov 17, 2009·The New England Journal of Medicine·Robert A HarringtonDeepak L Bhatt
Nov 17, 2009·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PLATFORM Investigators
Feb 25, 2010·JAMA : the Journal of the American Medical Association·Nicoline J BreetJurriën M ten Berg
Mar 31, 2010·Thrombosis and Haemostasis·José Luis FerreiroDominick J Angiolillo
Sep 11, 2010·Journal of the American College of Cardiology·Laurent BonelloUNKNOWN Working Group on High On-Treatment Platelet Reactivity
Jan 19, 2012·JAMA : the Journal of the American Medical Association·Dominick J AngiolilloUNKNOWN BRIDGE Investigators

❮ Previous
Next ❯

Citations

Nov 28, 2012·Journal of Thrombosis and Thrombolysis·José L FerreiroDominick J Angiolillo
Oct 22, 2013·Current Atherosclerosis Reports·Kiran KalraPaul A Gurbel
Mar 12, 2013·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PHOENIX Investigators
Dec 18, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Giuseppe PattiGermano Di Sciascio
Dec 24, 2013·Journal of Cardiovascular Translational Research·José Luis FerreiroAngel Cequier
Apr 26, 2014·Future Cardiology·Julie H Oestreich, Paul P Dobesh
Oct 1, 2014·Herz·D TrenkW Hochholzer
Dec 22, 2012·AJNR. American Journal of Neuroradiology·J Comin, D F Kallmes
Apr 30, 2013·Expert Review of Cardiovascular Therapy·David C YangDmitriy N Feldman
Feb 1, 2014·Expert Opinion on Pharmacotherapy·Joseph A Walsh, Matthew J Price
Oct 22, 2013·Expert Review of Cardiovascular Therapy·Francesco FranchiDominick J Angiolillo
Dec 19, 2015·Expert Opinion on Drug Safety·Francesco FranchiDominick J Angiolillo
Mar 3, 2015·Expert Opinion on Drug Metabolism & Toxicology·Eleonora Tamborini PermunianAlessandro Squizzato
Jan 8, 2014·Current Medical Research and Opinion·Jacek KubicaPaul Alfred Gurbel
Feb 13, 2016·Journal of the American College of Cardiology·Dominick J AngiolilloRoxana Mehran
Jan 24, 2016·Pharmacology & Therapeutics·Arman Qamar, Deepak L Bhatt
Sep 21, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jean-Philippe ColletGilles Montalescot
Oct 8, 2015·Coronary Artery Disease·David J Schneider
Aug 19, 2015·Nature Reviews. Cardiology·Fabiana RolliniDominick J Angiolillo
Apr 26, 2014·Thrombosis and Haemostasis·P AdamskiJ Kubica
Sep 19, 2015·Journal of Interventional Cardiology·David J SchneiderProspero Gogo
Mar 26, 2016·Journal of the American College of Cardiology·Fabiana RolliniDominick J Angiolillo
Mar 10, 2016·Expert Review of Cardiovascular Therapy·Davide Capodanno, Dominick J Angiolillo
Oct 13, 2016·Hospital Pharmacy·Danial E Baker, Kyle T Ingram
Jul 24, 2015·Drugs·Gillian M Keating
Jun 5, 2015·Platelets·Mark R Thomas, Robert F Storey
Jun 7, 2016·American Heart Journal·Cian P McCarthyJohn W McEvoy
Jun 22, 2015·American Heart Journal·Dimitrios AlexopoulosGregg W Stone
Mar 25, 2014·JACC. Cardiovascular Interventions·David J SchneiderProspero Gogo
May 6, 2014·The American Journal of Cardiology·Dimitrios AlexopoulosJohn Goudevenos
Feb 1, 2015·Trends in Molecular Medicine·Davide FerrariAndrea la Sala
Oct 8, 2014·Nature Reviews. Cardiology·Francesco Franchi, Dominick J Angiolillo
Jul 1, 2016·Expert Review of Cardiovascular Therapy·Robert F Storey, Akanksha Sinha
Sep 30, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Arman Qamar, Deepak L Bhatt
Jan 28, 2015·European Heart Journal. Acute Cardiovascular Care·Jozef L Van HerckPhilippe G Jorens
Jan 31, 2017·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Enrico FabrisGilles Montalescot
Aug 5, 2014·Coronary Artery Disease·David J SchneiderProspero Gogo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.